Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
BrightPath Biotherapeutics
company
About
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies.
- 11 - 50
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- ¥1.20B
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- May 8, 2003
- Number Of Employee
- 11 - 50
- Operating Status
- Active
BrightPath Biotherapeutics is a stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company develops products based on peptide vaccine technology that stimulates a potent immune response to tumor-associated antigens.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥1.20B
BrightPath Biotherapeutics has raised a total of
¥1.20B
in funding over 2 rounds. Their latest funding was raised on
Aug 29, 2014 from a Series Unknown round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 29, 2014 | Series Unknown | ¥1.20B | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
BrightPath Biotherapeutics is funded by 1 investors.
Ibis Capital Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Ibis Capital Partners
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
